• Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer U, Lehr C.M, Klotz U, Mürdter TE: Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA. J Pharm Sci 98(5): 1765-74 (2009)
• Buck MB, Coller J.K, Mürdter TE, Eichelbaum M, Knabbe C: TGFß2 and TßRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res Treat 107(1): 15-24 (2008)
• Heinkele G, Mürdter TE: Synthesis of [2H3]-labelled sulfamethoxazole and its main urinary metabolites. J Labelled Comp Radiopharm 50: 656-9 (2007)
• van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P,. Aulitzky WE: Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 6:86 (2006)
• Coller J.K, Krebsfaenger N, Klein K, Wobold R, Nüssler A, Neuhaus P, Zanger U, Eichelbaum M, Mürdter TE: Large inter-individual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br J Clin Pharmacol 57:105-11 (2004)
• Schiltmeyer B, Klingebiel T, Schwab M, Mürdter TE, Ritter C.A, Jenke A, Ehninger G, Gruhn B, Wurthwein G, Boos J, Hempel G: Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 52: 209-216 (2003)
• Mürdter TE, Friedel G, Backman J.T, McClellan M, Schick M, Gerken M, Bosslet K, Fritz P, Toomes H, Kroemer HK, Sperker B: Dose Optimisation of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumour pH Promotes Prodrug Activation by ß-Glucuronidase. J Pharmacol Exp Ther 301: 223-228 (2002)

• FORSYS Predicted Cancer Therapy: Investigation and Modelling of distribution and pharmacokinetics of therapeutic antibodies in the whole body, target organ (lung), and tumor as well as binding to targets on cancer cells and intracellular signalling. Partner institutions: University Stuttgart: IZI, IBVT, IST, IWS; University Magdeburg MaCS; University Tübingen Laboratory for Preclinical Imaging; Celonic GmbH Jülich, Bayer Technology Services, Leverkusen.

Principal Investigator at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart Germany
phone: ++49-711-8101 5974
fax: ++49-711-859295
email: thomas.muerdter@ikp-stuttgart.de

1984-1987	Undergraduate studies in Chemistry at University of Stuttgart
1988	Industrial traineeship at PLIVA Ltd. Zagreb, Yugoslavia
1988-1991	Graduate studies in Chemistry with elective subject Biochemistry at University of Stuttgart
1991	Diploma Thesis at the Department of Chemical Microbiology at the Fraunhofer Institute for Interfacial Engineering and Biotechnology: Degradation of trichloroethylene by the alcaligenes denitrificans ssp xylosoxidans strain JE95
1991-1992	Research fellow at the Fraunhofer Institute for Interfacial Engineering and Biotechnology
1992-1994	Deputy head of the Department of Polymer and Environmental Analysis at the Institute of Polymeric Sciences, Stuttgart, Germany
1994-1997	PhD studies at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
1997	PhD in Chemistry. Thesis: Distribution, tumour selectivity, and bio-activation of doxorubicin in the isolated perfused human lung model.
Since 1997	Scientist at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

Since 1998: Member of the DGTP (German Society of Toxicology and Pharmacology)